Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease. / Agentes anti-factor de necrosis tumoral en enfermedad de Crohn y colitis ulcerosa: más allá de la enfermedad luminal.
Gastroenterol Hepatol
; 41(9): 576-582, 2018 Nov.
Article
en En, Es
| MEDLINE
| ID: mdl-30054143
ABSTRACT
Anti-tumor necrosis factor agents (anti-TNF) drugs are commonly used in patients with inflammatory bowel disease (IBD) and have proven effective in both induction and maintenance therapy in luminal Crohn's disease and ulcerative colitis. Their efficacy has also been proven in fistulising perianal Crohn's disease. However, the evidence in other scenarios, such as stricturing, penetrating and non-fistulising perianal Crohn's disease, extraintestinal IBD manifestations and ileoanal reservoir complications, is not as robust. The aim of this review was to perform an analysis of the available literature and to determine the role of anti-TNF drugs in common clinical practice in patients affected by these complications.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Colitis Ulcerosa
/
Enfermedad de Crohn
/
Factor de Necrosis Tumoral alfa
/
Antirreumáticos
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
/
Es
Revista:
Gastroenterol Hepatol
Año:
2018
Tipo del documento:
Article